David R Fogelman

Summary

Affiliation: The University of Texas
Country: USA

Publications

  1. ncbi request reprint Emerging drugs for colorectal cancer
    David R Fogelman
    MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit 426, Houston, TX 77030, USA
    Expert Opin Emerg Drugs 13:629-42. 2008
  2. doi request reprint A predictive model of inflammatory markers and patient-reported symptoms for cachexia in newly diagnosed pancreatic cancer patients
    David R Fogelman
    Department of Gastrointestinal Medical Oncology, M D Anderson Cancer Center, 1515 Holcombe Blvd Unit 426, Houston, TX, 77030, USA
    Support Care Cancer . 2017
  3. pmc Does IGFR1 inhibition result in increased muscle mass loss in patients undergoing treatment for pancreatic cancer?
    David R Fogelman
    M D Anderson Cancer Center, 1515 Holcombe Drive, Houston, TX, 77030, USA
    J Cachexia Sarcopenia Muscle 5:307-13. 2014
  4. pmc Family history as a marker of platinum sensitivity in pancreatic adenocarcinoma
    David Fogelman
    Department of G I Medical Oncology, M D Anderson Cancer Center, 1515 Holcombe Blvd, Unit 426, Houston, TX, 77030, USA
    Cancer Chemother Pharmacol 76:489-98. 2015
  5. pmc Inhibition of the mammalian target of rapamycin (mTOR) in advanced pancreatic cancer: results of two phase II studies
    Milind M Javle
    Department of Gastrointestinal Medical Oncology, UT M D Anderson Cancer Center, Houston, TX, USA
    BMC Cancer 10:368. 2010
  6. ncbi request reprint Evidence for the efficacy of Iniparib, a PARP-1 inhibitor, in BRCA2-associated pancreatic cancer
    David R Fogelman
    M D Anderson Cancer Center, Houston, TX 77030, USA
    Anticancer Res 31:1417-20. 2011
  7. doi request reprint Bevacizumab plus gemcitabine and oxaliplatin as first-line therapy for metastatic or locally advanced pancreatic cancer: a phase II trial
    David Fogelman
    MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit 426, Houston, TX 77030, USA
    Cancer Chemother Pharmacol 68:1431-8. 2011
  8. doi request reprint The addition of erlotinib to gemcitabine and cisplatin does not appear to improve median survival in metastatic pancreatic cancer
    Mohamed A Khalil
    M D Anderson Cancer Center, 1515 Holcombe Blvd Unit 426, Houston, TX, 77030, USA
    Invest New Drugs 31:1375-83. 2013
  9. ncbi request reprint Use of operability classifications to predict outcome of patients with anatomically resectable pancreatic adenocarcinoma treated with neoadjuvant therapy
    Ching Wei David Tzeng
    University of Texas M D Anderson Cancer Center, Houston, TX
    J Clin Oncol 30:293. 2012
  10. doi request reprint Defined clinical classifications are associated with outcome of patients with anatomically resectable pancreatic adenocarcinoma treated with neoadjuvant therapy
    Ching Wei D Tzeng
    Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
    Ann Surg Oncol 19:2045-53. 2012

Detail Information

Publications16

  1. ncbi request reprint Emerging drugs for colorectal cancer
    David R Fogelman
    MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit 426, Houston, TX 77030, USA
    Expert Opin Emerg Drugs 13:629-42. 2008
    ..Our understanding of existing drugs, such as oxaliplatin and irinotecan, has become more refined. The incorporation of newer drugs such as bevacizumab and cetuximab has expanded treatment options as well...
  2. doi request reprint A predictive model of inflammatory markers and patient-reported symptoms for cachexia in newly diagnosed pancreatic cancer patients
    David R Fogelman
    Department of Gastrointestinal Medical Oncology, M D Anderson Cancer Center, 1515 Holcombe Blvd Unit 426, Houston, TX, 77030, USA
    Support Care Cancer . 2017
    ..We developed a model to predict the early onset of cachexia in advanced pancreatic cancer patients...
  3. pmc Does IGFR1 inhibition result in increased muscle mass loss in patients undergoing treatment for pancreatic cancer?
    David R Fogelman
    M D Anderson Cancer Center, 1515 Holcombe Drive, Houston, TX, 77030, USA
    J Cachexia Sarcopenia Muscle 5:307-13. 2014
    ..IGF-1 plays a role in the growth of multiple tumor types, including pancreatic cancer. IGF-1 also serves as a growth factor for muscle. The impact of therapeutic targeting of IGF-1 on muscle mass is unknown...
  4. pmc Family history as a marker of platinum sensitivity in pancreatic adenocarcinoma
    David Fogelman
    Department of G I Medical Oncology, M D Anderson Cancer Center, 1515 Holcombe Blvd, Unit 426, Houston, TX, 77030, USA
    Cancer Chemother Pharmacol 76:489-98. 2015
    ..While a subset of patients achieve prolonged survival, few of the factors that define this group of patients are known...
  5. pmc Inhibition of the mammalian target of rapamycin (mTOR) in advanced pancreatic cancer: results of two phase II studies
    Milind M Javle
    Department of Gastrointestinal Medical Oncology, UT M D Anderson Cancer Center, Houston, TX, USA
    BMC Cancer 10:368. 2010
    ..The addition of erlotinib to rapamycin can down-regulate rapamycin-stimulated Akt and results in synergistic antitumor activity with erlotinib in preclinical tumor models...
  6. ncbi request reprint Evidence for the efficacy of Iniparib, a PARP-1 inhibitor, in BRCA2-associated pancreatic cancer
    David R Fogelman
    M D Anderson Cancer Center, Houston, TX 77030, USA
    Anticancer Res 31:1417-20. 2011
    ..This case highlights the potential benefit for PARP inhibition in BRCA2-related pancreatic cancer...
  7. doi request reprint Bevacizumab plus gemcitabine and oxaliplatin as first-line therapy for metastatic or locally advanced pancreatic cancer: a phase II trial
    David Fogelman
    MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit 426, Houston, TX 77030, USA
    Cancer Chemother Pharmacol 68:1431-8. 2011
    ..The gemcitabine and oxaliplatin (GEMOX) has yielded among the longest progression-free survival durations in patients with advanced pancreatic cancer (APC). We postulated that adding bevacizumab would increase the effectiveness of GEMOX...
  8. doi request reprint The addition of erlotinib to gemcitabine and cisplatin does not appear to improve median survival in metastatic pancreatic cancer
    Mohamed A Khalil
    M D Anderson Cancer Center, 1515 Holcombe Blvd Unit 426, Houston, TX, 77030, USA
    Invest New Drugs 31:1375-83. 2013
    ..72). In conclusion, though there was a trend towards improved survival with the addition of erlotinib to gemcitabine and cisplatin, this does not reach statistical significance...
  9. ncbi request reprint Use of operability classifications to predict outcome of patients with anatomically resectable pancreatic adenocarcinoma treated with neoadjuvant therapy
    Ching Wei David Tzeng
    University of Texas M D Anderson Cancer Center, Houston, TX
    J Clin Oncol 30:293. 2012
    ..We sought to analyze resection rates, reasons for no resection, and outcomes after neoadjuvant therapy (NT) of patients with both resectable anatomy and either "operable" or "borderline" biology/physiology...
  10. doi request reprint Defined clinical classifications are associated with outcome of patients with anatomically resectable pancreatic adenocarcinoma treated with neoadjuvant therapy
    Ching Wei D Tzeng
    Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
    Ann Surg Oncol 19:2045-53. 2012
    ..By means of this system, we sought to analyze outcomes of patients with resectable anatomy but heterogeneous biology and physiology who were treated with neoadjuvant therapy...
  11. ncbi request reprint Can we identify patients with cancer at high risk for cachexia? A prospective study in pancreatic cancer (PC)
    David R Fogelman
    University of Texas M D Anderson Cancer Center, Houston, TX
    J Clin Oncol 30:219. 2012
    ..Symptoms such as pain, nausea and anorexia may predict weight loss. Inflammatory cytokines are also associated with cachexia. We evaluated the ability of each to predict weight loss in newly diagnosed PC patients...
  12. ncbi request reprint Patient-reported symptoms from patients with advanced pancreatic cancer undergoing gemcitabine-based chemotherapy
    Xin Shelley Wang
    University of Texas M D Anderson Cancer Center, Houston, TX
    J Clin Oncol 30:370. 2012
    ..We conducted a longitudinal study tracking multiple symptoms to provide an evidence-based symptom profile for patients with advanced PC receiving gemcitabine-based chemotherapy...
  13. doi request reprint Portal hypertension associated with oxaliplatin administration: clinical manifestations of hepatic sinusoidal injury
    Julian H Slade
    Department of Pharmacy, The University of Texas M D Anderson Cancer Center, Houston, 77030, USA
    Clin Colorectal Cancer 8:225-30. 2009
    ..The literature on hepatic sinusoidal injury after oxaliplatin is reviewed and the proposed pathophysiology is discussed...
  14. pmc Should combination chemotherapy serve as the backbone in clinical trials of advanced pancreatic cancer? A pooled analysis of phase II trials of gemcitabine-containing doublets plus bevacizumab
    Katherine Van Loon
    From the Division of Hematology and Oncology, Department of Medicine, University of California, San Francisco, San Francisco, CA Division of Cancer Medicine, Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX Department of Medicine, Roswell Park Cancer Institute, Buffalo, NY Digestive Disease Institute, Virginia Mason Medical Center, Seattle, WA Division of Medical Oncology, College of Medicine, The Ohio State University Medical Center, Columbus, OH Division of Biomedical Statistics and Informatics, Health Sciences Research Department, The Mayo Clinic, Rochester, MN and Division of Hematology and Oncology, The Mayo Clinic, Jacksonville, FL
    Pancreas 43:343-9. 2014
    ..The objective of this study was to evaluate whether building upon multidrug chemotherapy regimens represents a viable strategy in pancreatic cancer clinical trial design...
  15. ncbi request reprint Transforming growth factor (TGF) beta pathway and clinical outcome of pancreatic cancer
    Milind M Javle
    University of Texas M D Anderson Cancer Center, Houston, TX
    J Clin Oncol 30:201. 2012
    ..TGF-β exerts its effects through the TGF-beta-R1/ R2 receptors and the SMAD transcription regulators. We investigated the prognostic value of TGFβ signaling biomarkers in pancreatic cancer...
  16. pmc Prechemotherapy Touch Sensation Deficits Predict Oxaliplatin-Induced Neuropathy in Patients with Colorectal Cancer
    Xin Shelley Wang
    Department of Symptom Research, The University of Texas MD Anderson Cancer Center, Houston, Tex, USA
    Oncology 90:127-35. 2016
    ..Predicting which patients will likely develop CIPN is an ongoing clinical challenge...